ModerateAtypical antipsychotic – dopamine partial agonist×Macrolide antibiotic
Updated · Methodology
Mechanism
Erythromycin prolongs the QT interval on the electrocardiogram, and torsade de pointes and deaths have been reported with it (erythromycin labels). In clinical trials, aripiprazole prolonged the QT interval no more often than placebo. After marketing, however, QT prolongation, torsade de pointes, ventricular arrhythmia, cardiac arrest and sudden unexplained death have been reported (aripiprazole label). The liver breaks down aripiprazole through the enzymes CYP3A4 and CYP2D6, and erythromycin is a moderate CYP3A4 inhibitor (aripiprazole and erythromycin labels), so aripiprazole levels may rise. The labels do not say how much they rise with erythromycin. The strong CYP3A4 inhibitor ketoconazole raised the aripiprazole area under the concentration-time curve (AUC) by 63% and peak concentration by 37%. Weak inhibitors are expected to cause only small increases (aripiprazole label).
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes and other ventricular arrhythmias cause palpitations, dizziness or fainting. Higher aripiprazole levels bring more akathisia (inner restlessness), tremor and other extrapyramidal symptoms, drowsiness, fatigue, dizziness and a drop in blood pressure on standing up (aripiprazole label). The risk of arrhythmia is higher with low potassium or magnesium, bradycardia, coronary artery disease, severe heart failure, conduction disorders and in older people (erythromycin labels).
Management
Use the combination with caution: the aripiprazole and erythromycin labels ask for caution with any drug that prolongs the QT interval, and the aripiprazole label also asks for caution in patients with a family history of QT prolongation (aripiprazole label, European Medicines Agency, EMA, and erythromycin labels, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish label of one intravenous erythromycin product (Panpharma, registration number 79380) lists use with certain QT-prolonging neuroleptics among its contraindications without naming them. The labels of the original intravenous product and of oral forms ask only for caution with such drugs (erythromycin labels, AEMPS). The Panpharma label does not name aripiprazole, and the aripiprazole labels give no grounds to count it among these neuroleptics: in clinical trials QT prolongation was no more frequent than with placebo, and QT prolongation and torsade de pointes appear only among postmarketing reports (aripiprazole label). Erythromycin is contraindicated in patients with a history of QT prolongation or ventricular arrhythmia and in those with low potassium or magnesium (erythromycin labels). Check electrolytes when there are risk factors for imbalance (erythromycin labels). The labels require a lower aripiprazole dose only with strong CYP3A4 inhibitors, and erythromycin is a moderate one (aripiprazole and erythromycin labels). Watch for aripiprazole adverse effects and adjust the dose if they appear (oral erythromycin label). If the patient also takes a moderate CYP2D6 inhibitor, the starting aripiprazole dose may be reduced to a quarter of the usual dose and then adjusted to response (US aripiprazole label, Food and Drug Administration, FDA). If the aripiprazole dose was reduced, return it to the previous level after erythromycin is stopped (aripiprazole label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Abilify (aripiprazole) prescribing information (2014)
- AEMPS: Ficha técnica: Eritromicina (nº registro 79380), sección 4.3 (2025)– AEMPS, CIMA, nº registro 79380, sección 4.3
- FDA: E.E.S. (erythromycin ethylsuccinate) prescribing information (2025)– FDA, DailyMed, Carnegie Pharmaceuticals LLC, setid 91479d92-3bf3-4eb3-81bd-8ce4956d4347, revised 02/2025, Contraindications, Warnings – QT Prolongation, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión), revisión 09/2025, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Aripiprazol (EU/1/04/276), sección 4.5 (2026)– EMA, ficha técnica de Abilify comprimidos (EU/1/04/276), CIMA nº registro 04276007 (Abilify 10 mg comprimidos), información del producto actualizada 12/01/2026, secciones 4.2, 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Aripiprazol (nº registro 79317), sección 4.5 (2026)– AEMPS, CIMA, nº registro 79317 (Aripiprazol Cinfa 10 mg comprimidos EFG), revisión 02/2026, secciones 4.2, 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Eritromicina (nº registro 39690), sección 4.5 (2023)– AEMPS, CIMA, nº registro 39690 (Eritromicina Normon 500 mg comprimidos recubiertos EFG), revisión 05/2023, secciones 4.3, 4.4 y 4.5